RAW SEQUENCE LISTING PATENT APPLICATION US/08/443,982

DATE: 11/14/95 TIME: 16:09:01

INPUT SET: S7227.raw

This Raw Listing contains the General Information Section and up to the first 5 pages.

1		SEQUENCE LISTING PMTCO
2 3	(1) G	SEQUENCE LISTING SEQUENCE LISTING SEQUENCE LISTING
4	(-)	
5	(i)	APPLICANT: DIXIT, VISHVA M.
6 7	(ii)	TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REGULATING
8	(/	FAS-ASSOCIATED APOPTOSIS
9		
10	(iii)	NUMBER OF SEQUENCES: 7
11 12	/iv\	CORRESPONDENCE ADDRESS:
13	(14)	(A) ADDRESSEE: Morrison & Foerster
14		(B) STREET: 755 Page Mill Road
15		(C) CITY: Palo Alto
16		(D) STATE: CA
17		(E) COUNTRY: USA
18		(F) ZIP: 94304-1018
19	4>	GOVERNO DELDANCE FORM
20 21	(\(\)	COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk
22		(B) COMPUTER: IBM PC compatible
23		(C) OPERATING SYSTEM: PC-DOS/MS-DOS
24		(D) SOFTWARE: PatentIn Release #1.0, Version #1.30
25		
26	(Vi)	CURRENT APPLICATION DATA:
27		(A) APPLICATION NUMBER: US 08/443,982
28		(B) FILING DATE: 18-MAY-1995
29		(C) CLASSIFICATION:
30 31	/ ** i i i \	ATTORNEY/AGENT INFORMATION:
32	(\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	(A) NAME: Konski, Antoinette F.
33		(B) REGISTRATION NUMBER: 34,202
34		(C) REFERENCE/DOCKET NUMBER: 20344-21070.20
35		
36	(ix)	TELECOMMUNICATION INFORMATION:
37		(A) TELEPHONE: (415)813-5600
38		(B) TELEFAX: (415)494-0792
39		(C) TELEX: 706141 MRSNFOERS SFO
40 41		
42	(2) INFO	RMATION FOR SEQ ID NO:1:
43	(2) INFO	want four off ID HOLL.
44	(i)	SEQUENCE CHARACTERISTICS:
45		(A) LENGTH: 1642 base pairs
46		(B) TYPE: nucleic acid

RAW SEQUENCE LISTING PATENT APPLICATION US/08/443,982

INPUT SET: S7227.raw

DATE: 11/14/95

TIME: 16:09:04

```
47
               (C) STRANDEDNESS: single
48
               (D) TOPOLOGY: linear
49
50
         (ii) MOLECULE TYPE: cDNA
51
52
53
         (ix) FÉATURE:
               (A) NAME/KEY: CDS
54
55
               (B) LOCATION: 130..756
56
57
         (ix) FEATURE:
58
               (A) NAME/KEY: misc_feature
59
               (B) LOCATION: 4..6
60
               (D) OTHER INFORMATION: /note= "An in-frame stop codon 130
61
      base pairs upstream of the initiator methionine"
62
63
         (ix) FEATURE:
64
               (A) NAME/KEY: polyA signal
65
               (B) LOCATION: 1636..1641
66
               (D) OTHER INFORMATION: /note= "Potential poly(A)
67
      adenylation signal"
68
69
         (ix) FEATURE:
70
               (A) NAME/KEY: misc_feature
71
               (B) LOCATION: 198..753
72
               (D) OTHER INFORMATION: /note= "Clone-15, 5' end of FADD"
73
74
         (ix) FEATURE:
75
               (A) NAME/KEY: misc feature
               (B) LOCATION: 249..753
76
               (D) OTHER INFORMATION: /note= "Clone-8, 5' end of FADD"
77
78
79
         (ix) FEATURE:
80
               (A) NAME/KEY: misc_feature
81
               (B) LOCATION: 177..658
               (D) OTHER INFORMATION: /note= "Death Domain of FADD"
82
83
84
         (ix) FEATURE:
85
               (A) NAME/KEY: mutation
86
               (B) LOCATION: replace(490..492, "")
               (D) OTHER INFORMATION: /note= "For FADDmt, the sequence is
87
88
       altered to either AAT or AAC and the corresponding codon from
      Val to Asn"
89
90
91
         (ix) FEATURE:
92
               (A) NAME/KEY: misc feature
               (B) LOCATION: group (250...753, 232...753)
93
94
               (D) OTHER INFORMATION: /note= "Corresponding amino acids
95
      can comprise C-terminal polypeptide fragments of FADD"
96
97
         (ix) FEATURE:
98
               (A) NAME/KEY: misc feature
99
               (B) LOCATION: 253..753
```

RAW SEQUENCE LISTING PATENT APPLICATION US/08/443,982

DATE: 11/14/95 TIME: 16:09:08

INPUT SET: S7227.raw (D) OTHER INFORMATION: /note= "Corresponding amino acids can comprise a polypeptide fragment of FADD designated NFD-2" (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION: 310..753 (D) OTHER INFORMATION: /note= "Corresponding amino acids can comprise a polypeptide fragment of FADD designated NFD-3" (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION: 367..753 (D) OTHER INFORMATION: /note= "Corresponding amino acids can comprise polypeptide fragment of FADD designated NFD-4" (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION: 131..504 (D) OTHER INFORMATION: /note= "Corresponding amino acids can comprise an N-terminal half polypeptide fragment of FADD" (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION: 71..478 (D) OTHER INFORMATION: /note= "Corresponding amino acids can comprise an N-terminal half polypeptide fragment of FADD designated N-FADD" (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION: 133..501 (D) OTHER INFORMATION: /note= "Corresponding amino acids can comprise an N-terminal half polypeptide fragment of FADD" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: CTCTAAAGGT TCGGGGGTGG AATCCTTGGG CCGCTGGGCA AGCGGCGAGA CCTGGCCAGG GCCAGCGAGC CGAGGACAGA GGGCGCACGG AGGGCCGGGC CGCAGCCCCG GCCGCTTGCA GACCCCGCC ATG GAC CCG TTC CTG GTG CTG CTG CAC TCG GTG TCC Met Asp Pro Phe Leu Val Leu Leu His Ser Val Ser Ser AGC CTG TCG AGC AGC GAG CTG ACC GAG CTC AAG TTC CTA TGC CTC GGG Ser Leu Ser Ser Ser Glu Leu Thr Glu Leu Lys Phe Leu Cys Leu Gly CGC GTG GGC AAG CGC AAG CTG GAG CGC GTG CAG AGC GGC CTA GAC CTC Arg Val Gly Lys Arg Lys Leu Glu Arg Val Gln Ser Gly Leu Asp Leu

RAW SEQUENCE LISTING PATENT APPLICATION US/08/443,982

DATE: 11/14/95 TIME: 16:09:11

														IN	VPUT	SET: S	7227.raw
153 154						GAG Glu											312
155 156					50					55			1		60		
157	СТС	CTG	CGC	GAG	CTG	CTC	GCC	TCC	CTG	CGG	CGC	CAC	GAC	CTG	СТС	CGG	360
158						Leu											
159			5	65					70	9	5			75		5	
160																	
161	CGC	GTC	GAC	GAC	TTC	GAG	GCG	GGG	GCG	GCG	GCC	GGG	GCC	GCG	CCT	GGG	408
162	Arg	Val	Asp	Asp	Phe	Glu	Ala	Gly	Ala	Ala	Ala	Gly	Ala	Ala	Pro	Gly	
163			80					85					90				
164																	
165						GCA											456
166	Glu		Asp	Leu	Cys	Ala		Phe	Asn	Val	Ile	-	Asp	Asn	Val	Gly	
167		95					100					105					
168	* * *	a a m	maa		100	ama	aam.	000	a.a	ama		ama	ma.	a. a	100		504
169						CTG	_		_								504
170 171	110	ASP	тър	Arg	Arg	Leu 115	Ата	Arg	GIII	ren	120	var	ser	ASP	THE	Lys 125	
172	110					113					120					125	
173	ATC	GAC	AGC	ΔТС	GAG	GAC	ΔGΔ	ТΔС	ccc	CGC	AAC	СТС	ACA	GAG	ССТ	GTG	552
174						Asp											332
175					130		9	- , -		135					140		
176																	
177	CGG	GAG	TCA	CTG	AGA	ATC	TGG	AAG	AAC	ACA	GAG	AAG	GAG	AAC	GCA	ACA	600
178	Arg	Glu	Ser	Leu	Arg	Ile	Trp	Lys	Asn	Thr	Glu	Lys	Glu	Asn	Ala	Thr	
179				145	_			_	150			_		155			
180																	
181						GGG											648
182	Val	Ala		Leu	Val	Gly	Ala		Arg	Ser	Cys	Gln		Asn	Leu	Val	
183			160					165					170				
184	aam	asa	ama	OIII N	a	~~	amm	a.a	a.a	aaa	ООШ	a.a	аша	a.a		100	606
185 186						GAG Glu											696
187	мта	175	пеп	vaı	GIII	GIU	180	GIII	GIII	Ата	Arg	185	Leu	GIII	ASII	Arg	
188		113					100					103					
189	AGT	GGG	GCC	ATG	TCC	CCG	ATG	TCA	TGG	AAC	TCA	GAC	GCA	тст	ACC	TCC	744
190			_			Pro							_				,
191	190	-				195			•		200	-				205	
192																	
193	GAA	GCG	TCC	TGA	TGG	GCCG	CTG (TTTC	GCGC1	rg gj	CGGAC	CAC	A GGG	CATCI	CACA		796
194	Glu	Ala	Ser	*													
195																	
196																	
197	CAGO	CCTG	SAC !	rttg	STTC	rc To	CCAG	GAAG	TAC	3CCC <i>I</i>	AGCA	CTGT	rgaac	BAC (CCAG	CAGGAA	856
198																	
199	GCC	AGGC	rga (3TGA(CCA	CA GA	ACCAC	CCTG	TTC	TGA	ACTC	AAGC	TGC	TT 7	TATTA	ATGCC	916
200 201	mama	1000	73.07	12000		70 m	naaaa	100m		12020	ייים או	maa:	mmm	1000 -	יספסי		076
201	TOTO		JAC (AGG	(I	3C 1"	GGGG	CCTC	CAC	AGA'I	LATT	TCCF	1111C	TT C	CTCF	CTATG	976
202	ልሮልር	ነጥር! እ ሶ	י מים	ነር እጥሳ	ان ششد	יירי יייר	יר ג רח	ימממי	ር ርአር	ניייירי	ישמי	gggz	ሊርጥልረ	יייייני	2G A A 7	AGTTGG	1036
204	AUA(LIGH	.ca i	.oni(CAC	. AAA	. JAC			JJOF	1 A		- UNA	.51166	. 1038
205	AACC	CGTGT	rcc A	AGCAG	CAGA	AG GA	ATC	CTGC	AG	TGAC	CAG	TCAC	CACTO	TT A	ACTC	CACAGO	1096

RAW SEQUENCE LISTING PATENT APPLICATION US/08/443,982

DATE: 11/14/95 TIME: 16:09:15

INPUT SET: S7227.raw

206 207								-			
	GGAGGAGAC	AGCTC	AGAGG (CCCAGGA	ATC GG	AGCGAAGC	AGAGAG	GTGG	AGAA	CTGGGA	1156
208 209	TTTGAACCC	CGCCA!	rcctt (CACCAGA	GCC CA	TGCTCAAC	CACTGT	GGCG	TTCT	CTGCC	1216
210 211	CCTGCAGTT	GCAGA	AAGGA '	rgttttg	TCC CA	TTTCCTT G	GAGGCC	ACCG	GGAC	AGACCT	1276
212 213	GGACACTAG	GTCAG	GCGGG (GTGCTGT	GGT GG	GGAGAGGC	ATGGCT	GGGG	TGGG	GTGGG	1336
21 <u>4</u> 215	GAGACCTGGT	TGGCC	GTGGT (CCAGCTC	TTG GC	CCCTGTGT	GAGTTG	AGTC	TCCT	CTCTGA	1396
216 217	GACTGCTAAG	TAGGG	GCAGT (GATGGTT	GCC AG	GACGAATT	GAGATA	ATAT	CTGT	GAGGTG	1456
218 219	CTGATGAGT	ATTGAC	CACAC A	AGCACTC	TCT AA	ATCTTCCT	TGTGAG	GATT	ATGG	GTCCTG	1516
220 221	CAATTCTAC	GTTTC	TTACT (GTTTTG T	ATC AA	AATCACTA	TCTTTC	TGAT	AACA	GAATTG	1576
222 223 224	CCAAGGCAG	GGGAT	CTCGT 1	ATCTTTA	AAA AG	CAGTCCTC	TTATTO	CTAA	GGTA	ATCCTA	1636
225 226	ТТАААА										1642
									,		
227											
228	(2) INFORM	ATION I	FOR SE	ON DI C	:2:						
229											
230	(i)	SEQUE	VCE CH	ARACTER	TSTTCS	•					
-	\-	_									
231				H: 208		acids					
232		(B)	TYPE:	amino	acid						
233				OGY: li							
		(D)	TOPOL	JGI: II	Hear						
234											
235					ساد ساست						
	(11)	MOLECI	JI.E. TYI	PE: pro	TPIN						
	(11)	MOLECU	JLE TYI	PE: pro	tein						
236				_							
				_		Q ID NO:	2:				
236 237				_		Q ID NO:	2:				
236 237 238	(xi)	SEQUE	NCE DES	- SCRIPTI	ON: SE			- 0		G 2. 11	
236 237 238 239	(xi)	SEQUE	NCE DES Leu Val	- SCRIPTI	ON: SE			er Ser	: Leu	Ser	·
236 237 238	(xi)	SEQUE	NCE DES	- SCRIPTI	ON: SE			er Ser	Leu 15	Ser	·
236 237 238 239 240	(xi)	SEQUE	NCE DES Leu Val	- SCRIPTI	ON: SE	- Ser Val		er Ser		Ser	·
236 237 238 239 240 241	(xi) Met Asp Pr	SEQUEI	NCE DES Leu Val	- SCRIPTI l Leu L	ON: SEG	Ser Val	Ser Se		15		
236 237 238 239 240 241 242	(xi)	SEQUEI o Phe I	NCE DES Leu Val	- SCRIPTI l Leu L	ON: SE eu His ys Phe	Ser Val	Ser Se	y Arg	15 y Val		·
236 237 238 239 240 241	(xi) Met Asp Pr	SEQUEI	NCE DES Leu Val	- SCRIPTI l Leu L	ON: SEG	Ser Val	Ser Se		15 y Val		,
236 237 238 239 240 241 242	(xi) Met Asp Pr	SEQUEI o Phe I	NCE DES Leu Val	- SCRIPTI l Leu L	ON: SE eu His ys Phe	Ser Val	Ser Se	y Arg	15 y Val		·
236 237 238 239 240 241 242 243 244	(xi) Met Asp Pr 1 Ser Ser G	SEQUENCE OF Phe I	NCE DES Leu Val 5 Thr Glu	- SCRIPTI L Leu L	ON: SEC eu His ys Phe 25	Ser Val 10 Leu Cys	Ser Se	y Arg 30	15 y Val	Gly	
236 237 238 239 240 241 242 243 244 245	(xi) Met Asp Pr 1 Ser Ser Gl	SEQUENCE OF Phe II	NCE DES Leu Val 5 Thr Glu	SCRIPTI Leu L Leu L Val G	ON: SEC eu His ys Phe 25 ln Ser	Ser Val 10 Leu Cys	Ser Se	y Arg 30 au Phe	15 y Val	Gly	
236 237 238 239 240 241 242 243 244 245 246	(xi) Met Asp Pr 1 Ser Ser Gl	SEQUENCE OF Phe I	NCE DES Leu Val 5 Thr Glu	SCRIPTI Leu L Leu L Val G	ON: SEC eu His ys Phe 25	Ser Val 10 Leu Cys	Ser Se	y Arg 30	15 y Val	Gly	
236 237 238 239 240 241 242 243 244 245	(xi) Met Asp Pr 1 Ser Ser Gl	SEQUENCE OF Phe II	NCE DES Leu Val 5 Thr Glu	SCRIPTI Leu L Leu L Val G	ON: SEC eu His ys Phe 25 ln Ser	Ser Val 10 Leu Cys	Ser Se	y Arg 30 au Phe	15 y Val	Gly	
236 237 238 239 240 241 242 243 244 245 246	(xi) Met Asp Pr 1 Ser Ser Gl	SEQUENCE OF SEQUEN	NCE DES Leu Val 5 Thr Glu	SCRIPTI Leu L Leu L Val G	ON: SEC eu His ys Phe 25 ln Ser 40	Ser Val 10 Leu Cys Gly Leu	Ser Se	y Arg 30 eu Phe	15 y Val	Gly Met	·
236 237 238 239 240 241 242 243 244 245 246 247 248	(xi) Met Asp Pr 1 Ser Ser Gl Lys Arg Ly	SEQUENCE OF SEQUEN	NCE DES Leu Val 5 Thr Glu	SCRIPTI Leu L Leu L Val G	ON: SEC eu His ys Phe 25 ln Ser 40	Ser Val 10 Leu Cys Gly Leu	Ser Se Leu Gl Asp Le 4	y Arg 30 eu Phe	15 y Val	Gly Met	•
236 237 238 239 240 241 242 243 244 245 246 247 248 249	(xi) Met Asp Pr 1 Ser Ser Gl	SEQUENCE OF SEQUEN	NCE DES Leu Val 5 Thr Glu	SCRIPTI Leu L Leu L Val G	ON: SEC eu His ys Phe 25 ln Ser 40	Ser Val 10 Leu Cys Gly Leu	Ser Se	y Arg 30 eu Phe	15 y Val	Gly Met	
236 237 238 239 240 241 242 243 244 245 246 247 248 249 250	(xi) Met Asp Pr 1 Ser Ser Gl Lys Arg Ly 3 Leu Leu Gl 50	SEQUENCE OF THE PROPERTY OF TH	NCE DES Leu Val 5 Thr Glu Glu Arq	SCRIPTI Leu L Leu L Val G Leu G 55	ON: SEC eu His ys Phe 25 ln Ser 40	Ser Val 10 Leu Cys Gly Leu Gly His	Ser Ser Leu Gl Asp Le 4 Thr Gl	y Arg 30 u Phe 5	15 Val Ser Leu	Gly Met Arg	
236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251	(xi) Met Asp Pr 1 Ser Ser Gl Lys Arg Ly	SEQUENCE OF THE PROPERTY OF TH	NCE DES Leu Val 5 Thr Glu Glu Arq	SCRIPTI Leu L Leu L Val G Leu G 55	ON: SEC eu His ys Phe 25 ln Ser 40	Ser Val 10 Leu Cys Gly Leu Gly His	Ser Ser Leu Gl Asp Le 4 Thr Gl	y Arg 30 u Phe 5	15 Val Ser Leu	Gly Met Arg	
236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251	(xi) Met Asp Pr 1 Ser Ser Gl Lys Arg Ly 3 Leu Leu Gl 50	SEQUENCE OF THE PROPERTY OF TH	NCE DES Leu Val 5 Thr Glu Glu Arq	SCRIPTI Leu L Leu L G Val G D Leu G 55	ON: SEC eu His ys Phe 25 ln Ser 40	Ser Val 10 Leu Cys Gly Leu Gly His	Ser Ser Leu Gl Asp Le 4 Thr Gl	y Arg 30 u Phe 5	15 Val Ser Leu	Gly Met Arg	
236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252	Met Asp Pr 1 Ser Ser Gl Lys Arg Ly Leu Leu Gl 50 Glu Leu Le	SEQUENCE OF THE PROPERTY OF TH	NCE DES Leu Val 5 Thr Glu Glu Arq Asn Asp	SCRIPTI Leu L Leu L G Val G D Leu G 55	ON: SEC eu His ys Phe 25 ln Ser 40	Ser Val 10 Leu Cys Gly Leu Gly His	Ser Ser Leu Gl Asp Le 4 Thr Gl	y Arg 30 u Phe 5	15 Val Ser Leu	Gly Met Arg	
236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253	Met Asp Pr 1 Ser Ser Gl Lys Arg Ly 50 Clu Leu Leu Gl 65	SEQUENCE OF Phe II	NCE DES Leu Val 5 Thr Glu Glu Arg Asn Asp Ser Leu 70	SCRIPTI Leu L Leu L G Val G D Leu G 55	ON: SEG eu His ys Phe 25 ln Ser 40 lu Pro	Ser Val 10 Leu Cys Gly Leu Gly His Asp Leu 75	Ser Ser Leu Gl Asp Le 4 Thr Gl 60 Leu Ar	y Arg 30 u Phe 5	15 Val Ser Leu Val	Gly Met Arg Asp 80	
236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254	Met Asp Pr 1 Ser Ser Gl Lys Arg Ly Leu Leu Gl 50 Glu Leu Le	SEQUENCE OF Phe II	NCE DES Leu Val 5 Thr Glu Glu Arg Asn Asp Ser Leu 70	SCRIPTI Leu L Leu L G Val G D Leu G 55	ON: SEG eu His ys Phe 25 ln Ser 40 lu Pro	Ser Val 10 Leu Cys Gly Leu Gly His Asp Leu 75	Ser Ser Leu Gl Asp Le 4 Thr Gl 60 Leu Ar	y Arg 30 u Phe 5	15 Val Ser Leu Val	Gly Met Arg Asp 80	
236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253	Met Asp Pr 1 Ser Ser Gl Lys Arg Ly 50 Clu Leu Leu Gl 65	SEQUENCE OF Phe II	NCE DES Leu Val 5 Thr Glu Glu Arg Asn Asp Ser Leu 70	SCRIPTI Leu L Leu L G Val G D Leu G 55	ON: SEG eu His ys Phe 25 ln Ser 40 lu Pro	Ser Val 10 Leu Cys Gly Leu Gly His Asp Leu 75	Ser Ser Leu Gl Asp Le 4 Thr Gl 60 Leu Ar	y Arg 30 u Phe 5	15 Val Ser Leu Val	Gly Met Arg Asp 80	
236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255	Met Asp Pr 1 Ser Ser Gl Lys Arg Ly 50 Clu Leu Leu Gl 65	SEQUENCE OF Phe II	NCE DES Leu Val 5 Thr Glu Glu Arg Asn Asp Ser Leu 70	SCRIPTI Leu L Leu L G Val G D Leu G 55	ON: SEC eu His ys Phe 25 ln Ser 40 lu Pro	Ser Val 10 Leu Cys Gly Leu Gly His Asp Leu 75 Ala Ala	Ser Ser Leu Gl Asp Le 4 Thr Gl 60 Leu Ar	y Arg 30 u Phe 5	15 Val Ser Leu Val	Gly Met Arg Asp 80	
236 237 238 239 240 241 242 243 244 245 246 247 248 250 251 252 253 255 256	Met Asp Pr 1 Ser Ser Gl Lys Arg Ly Leu Leu Gl 50 Glu Leu Le 65 Asp Phe Gl	SEQUENCE OF Phe II Leu 12 20 25 Leu 05 Lu Gln 14 24 24 25 25 26 27 28 29 20 20 20 20 20 20 20 20 20	Leu Val 5 Thr Glu Glu Arg Asn Asp Ser Leu 70 Gly Ala	SCRIPTI Leu L Val G C S5 Arg A Ala A	ON: SEG eu His ys Phe 25 ln Ser 40 lu Pro rg His	Ser Val 10 Leu Cys Gly Leu Gly His Asp Leu 75 Ala Ala 90	Ser Ser Leu Gl Asp Le 4 Thr Gl 60 Leu Ar	y Arg 30 u Phe 5 u Leu y Glu	15 y Val Ser Leu y Val Glu 95	Gly Met Arg Asp 80 Asp	
236 237 238 239 241 242 243 244 245 246 247 248 250 251 252 253 256 257	Met Asp Pr 1 Ser Ser Gl Lys Arg Ly 50 Clu Leu Leu Gl 65	SEQUENCE OF Phe II Leu 12 20 25 Leu 0 25 Lu Gln 14 24 24 25 26 27 28 29 20 20 20 20 20 20 20 20 20	Leu Val 5 Thr Glu Glu Arg Asn Asp Ser Leu 70 Gly Ala	SCRIPTI Leu L Val G C S5 Arg A Ala A	ON: SEG eu His ys Phe 25 ln Ser 40 lu Pro rg His la Gly	Ser Val 10 Leu Cys Gly Leu Gly His Asp Leu 75 Ala Ala 90	Ser Ser Leu Gl Asp Le 4 Thr Gl 60 Leu Ar	y Arg	15 Val Ser Leu Val Glu 95 Asp	Gly Met Arg Asp 80 Asp	
236 237 238 239 240 241 242 243 244 245 246 247 248 250 251 252 253 255 256	Met Asp Pr 1 Ser Ser Gl Lys Arg Ly Leu Leu Gl 50 Glu Leu Le 65 Asp Phe Gl	SEQUENCE OF Phe II Leu 12 20 25 Leu 05 Lu Gln 14 24 24 25 25 26 27 28 29 20 20 20 20 20 20 20 20 20	Leu Val 5 Thr Glu Glu Arg Asn Asp Ser Leu 70 Gly Ala	SCRIPTI Leu L Val G C S5 Arg A Ala A	ON: SEG eu His ys Phe 25 ln Ser 40 lu Pro rg His	Ser Val 10 Leu Cys Gly Leu Gly His Asp Leu 75 Ala Ala 90	Ser Ser Leu Gl Asp Le 4 Thr Gl 60 Leu Ar	y Arg 30 u Phe 5 u Leu y Glu	15 Val Ser Leu Val Glu 95 Asp	Gly Met Arg Asp 80 Asp	

SEQUENCE VERIFICATION REPORT PATENT APPLICATION US/08/443,982

DATE: 11/14/95 TIME: 16:09:18

INPUT SET: S7227.raw

Line

Error

Original Text

278

Stop Codon at end of sequence removed - no error